Trending News Today: Coherus Sets Price of Biosimilar
Top news of the day from across the health care landscape
Officials with the FDA are planning to ban sales of most flavored e-cigarettes products in retail stores and gas stations in an effort to reduce tobacco use among teenagers, the New York Times reported. According to the article, the agency also plans to implement new rules to curb illegal sales of e-cigarette products to minors, such as age-verification requirements online. FDA Commissioner Scott Gottlieb, MD, had previously threatened a ban on the flavored products if 5 of the largest manufacturers did not come up with adequate plans to keep products from being sold to those under the age of 18, the article reported.
Coherus Biosciences Inc announced it will price Udenyca, its biosimilar to Amgen’s Neulasta (pegfilgrastim), at a 33% discount, Reuters reported. According to the article, the list price of $4175 per unit set by Coherus is the same as Mylan’s biosimilar Fulphila, which was approved earlier this year. Coherus plans to launch Udenyca on January 3, the article reported.
House Democrats are planning to hold a vote to protect individuals with pre-existing conditions, The Hill reported. According to the article, a House Democratic aide said the vote would be on a measure to have the House of Representatives formally intervene in an anti-Obamacare lawsuit to defend the health law. The lawsuit, which was brought by Texas and other GOP-led states, seeks to overturn all of Obamacare, the article reported.